0

Close
 
Upcoming Allied Market Research
2023
Veterinary/animal Vaccines Market

Veterinary/Animal Vaccines Market

by Product (Livestock Vaccines, Companion Animal Vaccines, Porcine Vaccines, Equine Vaccines, Poultry Vaccines, Aquaculture Vaccines, Other Animal Vaccines), by Technology (Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Toxoid Vaccines, Recombinant Vaccines, DNA Vaccines, Conjugate Vaccines) and by Diseases (Poultry Diseases, Companion Animal Disease, Livestock Diseases, Aquaculture Diseases, Other Diseases): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A00902
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Veterinary/animal Vaccines Market

Request Now !

Veterinary vaccines increase immunity of animals by improving animal health which avoids transmission of diseases from animals to humans. These vaccines can be given subcutaneously (under the skin) or intramuscularly (into the muscle) to animal. The aim of veterinary vaccines is to improve livestock production in a cost effective manner.  The rise in the incidences of zoonotic diseases are affecting humans and has led to increased interest in companion animal vaccines. Advancement in this area is mainly due to emergence of new zoonotic diseases, investment by government bodies and increased expenditures on animal health by pet lovers.

In recent years’ veterinary vaccines have made much impact on human health, welfare and production by developing novel vaccines which can target dangerous zoonotic diseases such as E. coli O157:H7, a food borne disease that can lead to HUS and kidney failure. Moreover, due to novel research in the field, expansion in the range of veterinary vaccines and formulations of adjuvants and reduction of pharmaceutical residuals in the human food chain will propel the growth of veterinary vaccines market. However, persistent economic slowdown, rising costs of storage and maintenance and the increase in the vegetarian population are major factors constituting to restraints of market. With improvement in costs, more investments in animal health and skilled expertise this market could have lucrative opportunities of growth.

The report segments the market on the basis of products, diseases, technologies and regions. On the basis of products market is categorized into companion animal vaccines, livestock, poultry, porcine, equine, aquaculture, and other animal vaccines. On the basis of technology, market is further segmented into inactivated vaccines, live attenuated vaccines, conjugate vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines and subunit vaccines. In terms of disease, it is classified to livestock diseases, aquaculture, poultry, companion diseases and others. Geographically, the market is analyzed in North America, Europe, Asia-Pacific and LAMEA.

Many companies are working in development of veterinary vaccines by undergoing collaboration between research institutions and companies, product approvals and launches, licensing agreements and partnerships amongst companies and augmented R&D investment on veterinary vaccines for instance, Zoetis announces product approval in 2013 for Rui Lan An Swine Vaccine for curing highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). Moreover, Bayer and BioNTech AG entered into agreement in 2016 for development of mRNA vaccines and therapeutics particularly for animal health. Ceva Santé Animale acquired Biovac Laboratories in 2016 which is a leading manufacturer of autogenous vaccines. These advancements in veterinary vaccines sector are indicative of the future growth in market.

Some of the key players of the market are Bayer Healthcare, Zoetis (Pfizer), Boehringer Ingelheim, Bioniche Animal Health, Ceva, Elcano Animal Health, Heska Co., Merck Animal Health, Merial (Sanofi), and Virbac.

KEY MARKET BENEFITS:

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global veterinary vaccines market.
  • Geographically, the veterinary vaccines are analyzed based on various regions such as North America, Europe, Asia-Pacific and LAMEA.
  • This study evaluating competitive landscape and value chain has been taken into account to help in understanding the competitive environment across the geographies.
  • Comprehensive analysis of factors that drive and restrict the growth of the global veterinary vaccines market is provided. For instance, increasing incidence of zoonotic disease and rising expenditure on animal health drives the market growth while cost of pet care and storage issues forms the restraints of market.
  • An in-depth analysis of current research and clinical developments within veterinary vaccines market is provided with key market dynamic factors that helps in understanding the behaviour of the market.
  • This report provides the quantitative analysis of the current market and estimations which assists in identifying the prevailing market opportunities.
  • Key market players within the veterinary vaccines market are profiled in this report and their strategies are analysed thoroughly, which helps in understanding competitive outlook of global veterinary products.

 Veterinary/Animal Vaccines Market Report Highlights

Aspects Details
By Product
  • Livestock Vaccines
  • Companion Animal Vaccines
  • Porcine Vaccines
  • Equine Vaccines
  • Poultry Vaccines
  • Aquaculture Vaccines
  • Other Animal Vaccines
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Middle East, South Africa, Rest of LAMEA)
By Technology
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • DNA Vaccines
  • Conjugate Vaccines
By Diseases
  • Poultry Diseases
  • Companion Animal Disease
  • Livestock Diseases
  • Aquaculture Diseases
  • Other Diseases
Key Market Players Zoetis (Pfizer), Bioniche Animal Health, Ceva, Virbac, Elcano Animal Health, Boehringer Ingelheim, Merck Animal Health, Heska Co., Merial (Sanofi), Bayer Healthcare
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: VETERINARY/ANIMAL VACCINES MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Livestock Vaccines

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Companion Animal Vaccines

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Porcine Vaccines

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Equine Vaccines

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Poultry Vaccines

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Aquaculture Vaccines

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Other Animal Vaccines

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

  • CHAPTER 5: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Technology

    • 5.2. Inactivated Vaccines

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Live Attenuated Vaccines

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Subunit Vaccines

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Toxoid Vaccines

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Recombinant Vaccines

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. DNA Vaccines

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Conjugate Vaccines

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: VETERINARY/ANIMAL VACCINES MARKET, BY DISEASES

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Diseases

    • 6.2. Poultry Diseases

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Companion Animal Disease

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Livestock Diseases

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Aquaculture Diseases

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Other Diseases

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: VETERINARY/ANIMAL VACCINES MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Technology

      • 7.2.4. Market Size and Forecast, By Diseases

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Veterinary/animal Vaccines Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Technology
        • 7.2.6.3. Market Size and Forecast, By Diseases

      • 7.2.7. Canada Veterinary/animal Vaccines Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Technology
        • 7.2.7.3. Market Size and Forecast, By Diseases

      • 7.2.8. Mexico Veterinary/animal Vaccines Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Technology
        • 7.2.8.3. Market Size and Forecast, By Diseases

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Technology

      • 7.3.4. Market Size and Forecast, By Diseases

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Veterinary/animal Vaccines Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Technology
        • 7.3.6.3. Market Size and Forecast, By Diseases

      • 7.3.7. Germany Veterinary/animal Vaccines Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Technology
        • 7.3.7.3. Market Size and Forecast, By Diseases

      • 7.3.8. Italy Veterinary/animal Vaccines Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Technology
        • 7.3.8.3. Market Size and Forecast, By Diseases

      • 7.3.9. Spain Veterinary/animal Vaccines Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Technology
        • 7.3.9.3. Market Size and Forecast, By Diseases

      • 7.3.10. UK Veterinary/animal Vaccines Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Technology
        • 7.3.10.3. Market Size and Forecast, By Diseases

      • 7.3.11. Russia Veterinary/animal Vaccines Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Technology
        • 7.3.11.3. Market Size and Forecast, By Diseases

      • 7.3.12. Rest Of Europe Veterinary/animal Vaccines Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Technology
        • 7.3.12.3. Market Size and Forecast, By Diseases

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Technology

      • 7.4.4. Market Size and Forecast, By Diseases

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Veterinary/animal Vaccines Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Technology
        • 7.4.6.3. Market Size and Forecast, By Diseases

      • 7.4.7. Japan Veterinary/animal Vaccines Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Technology
        • 7.4.7.3. Market Size and Forecast, By Diseases

      • 7.4.8. India Veterinary/animal Vaccines Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Technology
        • 7.4.8.3. Market Size and Forecast, By Diseases

      • 7.4.9. South Korea Veterinary/animal Vaccines Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Technology
        • 7.4.9.3. Market Size and Forecast, By Diseases

      • 7.4.10. Australia Veterinary/animal Vaccines Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Technology
        • 7.4.10.3. Market Size and Forecast, By Diseases

      • 7.4.11. Thailand Veterinary/animal Vaccines Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Technology
        • 7.4.11.3. Market Size and Forecast, By Diseases

      • 7.4.12. Malaysia Veterinary/animal Vaccines Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Technology
        • 7.4.12.3. Market Size and Forecast, By Diseases

      • 7.4.13. Indonesia Veterinary/animal Vaccines Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Technology
        • 7.4.13.3. Market Size and Forecast, By Diseases

      • 7.4.14. Rest of Asia Pacific Veterinary/animal Vaccines Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Technology
        • 7.4.14.3. Market Size and Forecast, By Diseases

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Technology

      • 7.5.4. Market Size and Forecast, By Diseases

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Veterinary/animal Vaccines Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Technology
        • 7.5.6.3. Market Size and Forecast, By Diseases

      • 7.5.7. South Africa Veterinary/animal Vaccines Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Technology
        • 7.5.7.3. Market Size and Forecast, By Diseases

      • 7.5.8. Saudi Arabia Veterinary/animal Vaccines Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Technology
        • 7.5.8.3. Market Size and Forecast, By Diseases

      • 7.5.9. UAE Veterinary/animal Vaccines Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Technology
        • 7.5.9.3. Market Size and Forecast, By Diseases

      • 7.5.10. Argentina Veterinary/animal Vaccines Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Technology
        • 7.5.10.3. Market Size and Forecast, By Diseases

      • 7.5.11. Rest of LAMEA Veterinary/animal Vaccines Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Technology
        • 7.5.11.3. Market Size and Forecast, By Diseases

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Bayer Healthcare

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Zoetis (Pfizer)

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Boehringer Ingelheim

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Bioniche Animal Health

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Ceva

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Elcano Animal Health

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Heska Co.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Merck Animal Health

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Merial (Sanofi)

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Virbac

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR LIVESTOCK VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR COMPANION ANIMAL VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR PORCINE VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR EQUINE VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR POULTRY VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR AQUACULTURE VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR OTHER ANIMAL VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR SUBUNIT VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR RECOMBINANT VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR DNA VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR CONJUGATE VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR POULTRY DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR COMPANION ANIMAL DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR LIVESTOCK DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR AQUACULTURE DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL VETERINARY/ANIMAL VACCINES MARKET FOR OTHER DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA VETERINARY/ANIMAL VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 28. U.S. VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. U.S. VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 30. U.S. VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 31. CANADA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. CANADA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 33. CANADA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE VETERINARY/ANIMAL VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 47. ITALY VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. ITALY VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 49. ITALY VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 53. UK VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. UK VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 55. UK VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 56. RUSSIA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. RUSSIA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 59. REST OF EUROPE VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 60. REST OF EUROPE VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 61. REST OF EUROPE VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 62. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 63. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 65. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 66. CHINA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. CHINA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 68. CHINA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 69. JAPAN VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. JAPAN VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 71. JAPAN VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 72. INDIA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. INDIA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 74. INDIA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 75. SOUTH KOREA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 76. SOUTH KOREA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 77. SOUTH KOREA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 78. AUSTRALIA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 79. AUSTRALIA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 80. AUSTRALIA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 81. THAILAND VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 82. THAILAND VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 83. THAILAND VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 84. MALAYSIA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 85. MALAYSIA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 86. MALAYSIA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 87. INDONESIA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 88. INDONESIA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 89. INDONESIA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 90. REST OF ASIA PACIFIC VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 91. REST OF ASIA PACIFIC VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 92. REST OF ASIA PACIFIC VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA VETERINARY/ANIMAL VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 94. LAMEA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 95. LAMEA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 96. LAMEA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 97. BRAZIL VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 98. BRAZIL VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 99. BRAZIL VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 100. SOUTH AFRICA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 101. SOUTH AFRICA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 102. SOUTH AFRICA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 103. SAUDI ARABIA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 104. SAUDI ARABIA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 105. SAUDI ARABIA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 106. UAE VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 107. UAE VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 108. UAE VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 109. ARGENTINA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 110. ARGENTINA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 111. ARGENTINA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 112. REST OF LAMEA VETERINARY/ANIMAL VACCINES, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 113. REST OF LAMEA VETERINARY/ANIMAL VACCINES, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA VETERINARY/ANIMAL VACCINES, BY DISEASES, 2022-2032 ($MILLION)
  • TABLE 115. BAYER HEALTHCARE: KEY EXECUTIVES
  • TABLE 116. BAYER HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 117. BAYER HEALTHCARE: OPERATING SEGMENTS
  • TABLE 118. BAYER HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 119. BAYER HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. ZOETIS (PFIZER): KEY EXECUTIVES
  • TABLE 121. ZOETIS (PFIZER): COMPANY SNAPSHOT
  • TABLE 122. ZOETIS (PFIZER): OPERATING SEGMENTS
  • TABLE 123. ZOETIS (PFIZER): PRODUCT PORTFOLIO
  • TABLE 124. ZOETIS (PFIZER): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 126. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 127. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 128. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 129. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. BIONICHE ANIMAL HEALTH: KEY EXECUTIVES
  • TABLE 131. BIONICHE ANIMAL HEALTH: COMPANY SNAPSHOT
  • TABLE 132. BIONICHE ANIMAL HEALTH: OPERATING SEGMENTS
  • TABLE 133. BIONICHE ANIMAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 134. BIONICHE ANIMAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. CEVA: KEY EXECUTIVES
  • TABLE 136. CEVA: COMPANY SNAPSHOT
  • TABLE 137. CEVA: OPERATING SEGMENTS
  • TABLE 138. CEVA: PRODUCT PORTFOLIO
  • TABLE 139. CEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. ELCANO ANIMAL HEALTH: KEY EXECUTIVES
  • TABLE 141. ELCANO ANIMAL HEALTH: COMPANY SNAPSHOT
  • TABLE 142. ELCANO ANIMAL HEALTH: OPERATING SEGMENTS
  • TABLE 143. ELCANO ANIMAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 144. ELCANO ANIMAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. HESKA CO.: KEY EXECUTIVES
  • TABLE 146. HESKA CO.: COMPANY SNAPSHOT
  • TABLE 147. HESKA CO.: OPERATING SEGMENTS
  • TABLE 148. HESKA CO.: PRODUCT PORTFOLIO
  • TABLE 149. HESKA CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. MERCK ANIMAL HEALTH: KEY EXECUTIVES
  • TABLE 151. MERCK ANIMAL HEALTH: COMPANY SNAPSHOT
  • TABLE 152. MERCK ANIMAL HEALTH: OPERATING SEGMENTS
  • TABLE 153. MERCK ANIMAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 154. MERCK ANIMAL HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. MERIAL (SANOFI): KEY EXECUTIVES
  • TABLE 156. MERIAL (SANOFI): COMPANY SNAPSHOT
  • TABLE 157. MERIAL (SANOFI): OPERATING SEGMENTS
  • TABLE 158. MERIAL (SANOFI): PRODUCT PORTFOLIO
  • TABLE 159. MERIAL (SANOFI): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. VIRBAC: KEY EXECUTIVES
  • TABLE 161. VIRBAC: COMPANY SNAPSHOT
  • TABLE 162. VIRBAC: OPERATING SEGMENTS
  • TABLE 163. VIRBAC: PRODUCT PORTFOLIO
  • TABLE 164. VIRBAC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET
  • FIGURE 3. SEGMENTATION VETERINARY/ANIMAL VACCINES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN VETERINARY/ANIMAL VACCINES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVETERINARY/ANIMAL VACCINES MARKET
  • FIGURE 11. VETERINARY/ANIMAL VACCINES MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. VETERINARY/ANIMAL VACCINES MARKET FOR LIVESTOCK VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. VETERINARY/ANIMAL VACCINES MARKET FOR COMPANION ANIMAL VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. VETERINARY/ANIMAL VACCINES MARKET FOR PORCINE VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. VETERINARY/ANIMAL VACCINES MARKET FOR EQUINE VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. VETERINARY/ANIMAL VACCINES MARKET FOR POULTRY VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. VETERINARY/ANIMAL VACCINES MARKET FOR AQUACULTURE VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. VETERINARY/ANIMAL VACCINES MARKET FOR OTHER ANIMAL VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. VETERINARY/ANIMAL VACCINES MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 20. VETERINARY/ANIMAL VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. VETERINARY/ANIMAL VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. VETERINARY/ANIMAL VACCINES MARKET FOR SUBUNIT VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. VETERINARY/ANIMAL VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. VETERINARY/ANIMAL VACCINES MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. VETERINARY/ANIMAL VACCINES MARKET FOR DNA VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. VETERINARY/ANIMAL VACCINES MARKET FOR CONJUGATE VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. VETERINARY/ANIMAL VACCINES MARKET SEGMENTATION, BY BY DISEASES
  • FIGURE 28. VETERINARY/ANIMAL VACCINES MARKET FOR POULTRY DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. VETERINARY/ANIMAL VACCINES MARKET FOR COMPANION ANIMAL DISEASE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. VETERINARY/ANIMAL VACCINES MARKET FOR LIVESTOCK DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. VETERINARY/ANIMAL VACCINES MARKET FOR AQUACULTURE DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. VETERINARY/ANIMAL VACCINES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 34. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 35. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 36. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 37. COMPETITIVE DASHBOARD
  • FIGURE 38. COMPETITIVE HEATMAP: VETERINARY/ANIMAL VACCINES MARKET
  • FIGURE 39. Top player positioning, 2022
  • FIGURE 40. BAYER HEALTHCARE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. BAYER HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. BAYER HEALTHCARE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. ZOETIS (PFIZER): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. ZOETIS (PFIZER): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. ZOETIS (PFIZER): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. BOEHRINGER INGELHEIM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. BIONICHE ANIMAL HEALTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. BIONICHE ANIMAL HEALTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. BIONICHE ANIMAL HEALTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. CEVA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. CEVA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. CEVA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. ELCANO ANIMAL HEALTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. ELCANO ANIMAL HEALTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. ELCANO ANIMAL HEALTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. HESKA CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. HESKA CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. HESKA CO.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. MERCK ANIMAL HEALTH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. MERCK ANIMAL HEALTH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. MERCK ANIMAL HEALTH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. MERIAL (SANOFI): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. MERIAL (SANOFI): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. MERIAL (SANOFI): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. VIRBAC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. VIRBAC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. VIRBAC: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Veterinary/animal Vaccines Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers